<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00037765</url>
  </required_header>
  <id_info>
    <org_study_id>00-1420</org_study_id>
    <secondary_id>5R01HL068890</secondary_id>
    <nct_id>NCT00037765</nct_id>
  </id_info>
  <brief_title>Gene Modifiers of Cystic Fibrosis Lung Disease</brief_title>
  <official_title>Gene Modifiers of Cystic Fibrosis Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine genetic modifiers of the severity of cystic fibrosis
      lung disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Cystic Fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance
      regulator (CFTR) gene resulting in impaired chloride transport across epithelial cells. While
      many organs are involved, infection, inflammation and destruction of the lungs ultimately
      result in morbidity and mortality. There is an association between residual CFTR function and
      severity of disease, however there is great variability within specific mutations suggesting
      gene modifiers. Even though there are over 900 mutations in CFTR that are related to CF lung
      disease, F508 the most common one is represented in 70 percent of the American CF population.
      Thus, establishing a phenotype/genotype correlation using homozygote F508 patients is likely
      to identify genes that are responsible for a mild form of disease. Why is this important?
      Whereas since the identification of the gene CFTR a significant amount of knowledge has been
      accumulated on CFTR function and CF pathogenesis, the cure for CF (treated as a monogenic
      disease) has been elusive. Identification of genetic modifiers (that may explain why 10
      percent of CF patients died before the age of 10, 1/3 before the age of 20 while 50 percent
      live over 32 years of age) should expand the therapeutic targets that may lead to shifting of
      the severe phenotypes to milder ones. Moreover, the approach outlined in this study may also
      result in a better understanding of CFTR and delta F508 biogenesis and function, as it may
      identify genes directly related to CFTR.

      The study is in response to a Request for Applications titled &quot;Genetic Modifiers of Single
      Gene Defect Diseases&quot; released in August, 2000 and co-sponsored by the National Institute of
      Diabetes, Digestive, and Kidney Diseases.

      DESIGN NARRATIVE:

      Patients with cystic fibrosis (CF) display a wide range of disease severity, particularly in
      pulmonary phenotype. Although some of this variability can be attributed to specific
      mutations within the CFTR gene (allelic heterogeneity), much of this variability has not been
      adequately explained. The central hypothesis of the study is that much of the &quot;severity&quot; (or
      &quot;mildness&quot;) of CF lung disease reflects the influence of non-CFTR &quot;modifier&quot; alleles (genes).
      The study is designed to identify associations between non-CFTR genes and the pulmonary
      phenotype. To accomplish this goal, studies will be conducted on 600 CF patients who have the
      same CFTR genetic background, i.e., homozygous deltaF508, and who are at the extremes of
      pulmonary phenotype, i.e., the most severe and mildest lung disease. Pulmonary disease
      severity (or mildness) will be quantitated by longitudinal lung function analysis with
      informative censoring. The overall strategy will be to test for the association of candidate
      modifier alleles (genes) with the severity (or mildness) of pulmonary disease. Key clinical
      features (gender; age-at-diagnosis; sweat chloride; nutrition; and respiratory microbiology)
      will be important variables in the overall analysis. Initially, the study will test candidate
      genes (n=200) that have been implicated in the pathophysiology of CF lung disease. A pooling
      strategy will be used to expedite the first rounds of testing. After pooling DNA from the
      &quot;severe&quot; patients, and pooling DNA from the mild patients, those genes (alleles) can be
      identified with the greatest association with phenotype. Follow-up genotyping in individual
      subjects will allow subgroup analyses (gender; age-at-diagnosis; nutrition; respiratory
      microbiology) for each gene, as well as more complex analyses to search for interaction among
      different alleles. Subsequent studies will involve genome-wide testing with single nucleotide
      polymorphisms (SNPs) to identify loci (and genes) that are not present in the initial list of
      candidate genes. Identification of genes that modulate the severity of the pulmonary
      phenotype will improve understanding of the pathophysiology of CF lung disease, and identify
      new targets for therapeutic intervention.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>This is not an interventional study.</measure>
    <time_frame>This is not an interventional study</time_frame>
    <description>Not applicable. This is not an interventional study.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Lung Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        CF patients who have the same CFTR genetic background, i.e., homozygous deltaF508, and who
        are at the extremes of pulmonary phenotype, i.e., the most severe and mildest lung disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with CF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Knowles</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTRC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cfmod.med.unc.edu/</url>
    <description>This is the website for this study.</description>
  </link>
  <reference>
    <citation>Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295.</citation>
    <PMID>19738092</PMID>
  </reference>
  <results_reference>
    <citation>Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR; Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005 Oct 6;353(14):1443-53.</citation>
    <PMID>16207846</PMID>
  </results_reference>
  <results_reference>
    <citation>Taylor-Cousar JL, Zariwala MA, Burch LH, Pace RG, Drumm ML, Calloway H, Fan H, Weston BW, Wright FA, Knowles MR; Gene Modifier Study Group. Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PLoS One. 2009;4(1):e4270. doi: 10.1371/journal.pone.0004270. Epub 2009 Jan 26.</citation>
    <PMID>19169360</PMID>
  </results_reference>
  <results_reference>
    <citation>Levy H, Murphy A, Zou F, Gerard C, Klanderman B, Schuemann B, Lazarus R, García KC, Celedón JC, Drumm M, Dahmer M, Quasney M, Schneck K, Reske M, Knowles MR, Pier GB, Lange C, Weiss ST. IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatr Pulmonol. 2009 Jun;44(6):580-93. doi: 10.1002/ppul.21026.</citation>
    <PMID>19431193</PMID>
  </results_reference>
  <results_reference>
    <citation>Gu Y, Harley IT, Henderson LB, Aronow BJ, Vietor I, Huber LA, Harley JB, Kilpatrick JR, Langefeld CD, Williams AH, Jegga AG, Chen J, Wills-Karp M, Arshad SH, Ewart SL, Thio CL, Flick LM, Filippi MD, Grimes HL, Drumm ML, Cutting GR, Knowles MR, Karp CL. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature. 2009 Apr 23;458(7241):1039-42. doi: 10.1038/nature07811. Epub 2009 Feb 25.</citation>
    <PMID>19242412</PMID>
  </results_reference>
  <results_reference>
    <citation>Li W, Sun L, Corey M, Zou F, Lee S, Cojocaru AL, Taylor C, Blackman SM, Stephenson A, Sandford AJ, Dorfman R, Drumm ML, Cutting GR, Knowles MR, Durie P, Wright FA, Strug LJ. Understanding the population structure of North American patients with cystic fibrosis. Clin Genet. 2011 Feb;79(2):136-46. doi: 10.1111/j.1399-0004.2010.01502.x.</citation>
    <PMID>20681990</PMID>
  </results_reference>
  <results_reference>
    <citation>Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM, Corey M, Dorfman R, Goddard K, Green D, Kent JW Jr, Lange EM, Lee S, Li W, Luo J, Mayhew GM, Naughton KM, Pace RG, Paré P, Rommens JM, Sandford A, Stonebraker JR, Sun W, Taylor C, Vanscoy LL, Zou F, Blangero J, Zielenski J, O'Neal WK, Drumm ML, Durie PR, Knowles MR, Cutting GR. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet. 2011 Jun;43(6):539-46. doi: 10.1038/ng.838. Epub 2011 May 22.</citation>
    <PMID>21602797</PMID>
  </results_reference>
  <results_reference>
    <citation>Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med. 2006 Oct 1;174(7):780-6. Epub 2006 Jul 20.</citation>
    <PMID>16858011</PMID>
  </results_reference>
  <results_reference>
    <citation>Knowles MR. Gene modifiers of lung disease. Curr Opin Pulm Med. 2006 Nov;12(6):416-21. Review.</citation>
    <PMID>17053491</PMID>
  </results_reference>
  <results_reference>
    <citation>Bartling TR, Drumm ML. Oxidative stress causes IL8 promoter hyperacetylation in cystic fibrosis airway cell models. Am J Respir Cell Mol Biol. 2009 Jan;40(1):58-65. doi: 10.1165/rcmb.2007-0464OC. Epub 2008 Jul 17.</citation>
    <PMID>18635816</PMID>
  </results_reference>
  <results_reference>
    <citation>Hillian AD, Londono D, Dunn JM, Goddard KA, Pace RG, Knowles MR, Drumm ML; CF Gene Modifier Study Group. Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun. 2008 Sep;9(6):501-8. doi: 10.1038/gene.2008.42. Epub 2008 Jun 19.</citation>
    <PMID>18563170</PMID>
  </results_reference>
  <results_reference>
    <citation>Darrah R, McKone E, O'Connor C, Rodgers C, Genatossio A, McNamara S, Gibson R, Stuart Elborn J, Ennis M, Gallagher CG, Kalsheker N, Aitken M, Wiese D, Dunn J, Smith P, Pace R, Londono D, Goddard KA, Knowles MR, Drumm ML. EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiol Genomics. 2010 Mar 3;41(1):71-7. doi: 10.1152/physiolgenomics.00185.2009. Epub 2009 Dec 22.</citation>
    <PMID>20028935</PMID>
  </results_reference>
  <results_reference>
    <citation>Bezzerri V, d'Adamo P, Rimessi A, Lanzara C, Crovella S, Nicolis E, Tamanini A, Athanasakis E, Tebon M, Bisoffi G, Drumm ML, Knowles MR, Pinton P, Gasparini P, Berton G, Cabrini G. Phospholipase C-β3 is a key modulator of IL-8 expression in cystic fibrosis bronchial epithelial cells. J Immunol. 2011 Apr 15;186(8):4946-58. doi: 10.4049/jimmunol.1003535. Epub 2011 Mar 16.</citation>
    <PMID>21411730</PMID>
  </results_reference>
  <results_reference>
    <citation>Harris WT, Muhlebach MS, Oster RA, Knowles MR, Clancy JP, Noah TL. Plasma TGF-β₁ in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy. Pediatr Pulmonol. 2011 Jul;46(7):688-95. doi: 10.1002/ppul.21430. Epub 2011 Feb 18.</citation>
    <PMID>21337732</PMID>
  </results_reference>
  <results_reference>
    <citation>Harris WT, Muhlebach MS, Oster RA, Knowles MR, Noah TL. Transforming growth factor-beta(1) in bronchoalveolar lavage fluid from children with cystic fibrosis. Pediatr Pulmonol. 2009 Nov;44(11):1057-64. doi: 10.1002/ppul.21079.</citation>
    <PMID>19830844</PMID>
  </results_reference>
  <results_reference>
    <citation>Guo X, Pace RG, Stonebraker JR, Commander CW, Dang AT, Drumm ML, Harris A, Zou F, Swallow DM, Wright FA, O'Neal WK, Knowles MR. Mucin variable number tandem repeat polymorphisms and severity of cystic fibrosis lung disease: significant association with MUC5AC. PLoS One. 2011;6(10):e25452. doi: 10.1371/journal.pone.0025452. Epub 2011 Oct 6.</citation>
    <PMID>21998660</PMID>
  </results_reference>
  <results_reference>
    <citation>Mencin A, Seki E, Osawa Y, Kodama Y, De Minicis S, Knowles M, Brenner DA. Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology. 2007 Nov;46(5):1443-52.</citation>
    <PMID>17668872</PMID>
  </results_reference>
  <results_reference>
    <citation>Blackman SM, Hsu S, Ritter SE, Naughton KM, Wright FA, Drumm ML, Knowles MR, Cutting GR. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia. 2009 Sep;52(9):1858-65. doi: 10.1007/s00125-009-1436-2. Epub 2009 Jul 8.</citation>
    <PMID>19585101</PMID>
  </results_reference>
  <results_reference>
    <citation>Taylor C, Commander CW, Collaco JM, Strug LJ, Li W, Wright FA, Webel AD, Pace RG, Stonebraker JR, Naughton K, Dorfman R, Sandford A, Blackman SM, Berthiaume Y, Paré P, Drumm ML, Zielenski J, Durie P, Cutting GR, Knowles MR, Corey M. A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies. Pediatr Pulmonol. 2011 Sep;46(9):857-69. doi: 10.1002/ppul.21456. Epub 2011 Apr 1.</citation>
    <PMID>21462361</PMID>
  </results_reference>
  <results_reference>
    <citation>Zou F, Lee S, Knowles MR, Wright FA. Quantification of population structure using correlated SNPs by shrinkage principal components. Hum Hered. 2010;70(1):9-22. doi: 10.1159/000288706. Epub 2010 Apr 23.</citation>
    <PMID>20413978</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2002</study_first_submitted>
  <study_first_submitted_qc>May 20, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2002</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

